1. Relative inhibitory activities of newly developed diazabicyclooctanes, boronic acid derivatives, and penicillin-based sulfone β-lactamase inhibitors against broad-spectrum AmpC β-lactamases.
- Author
-
Le Terrier C, Mlynarcik P, Sadek M, Nordmann P, and Poirel L
- Subjects
- Penicillins pharmacology, Penicillins chemistry, Sulfones pharmacology, Sulfones chemistry, Bridged Bicyclo Compounds, Heterocyclic pharmacology, Bridged Bicyclo Compounds, Heterocyclic chemistry, Lactams, Piperidines, Cyclooctanes, Azabicyclo Compounds pharmacology, Azabicyclo Compounds chemistry, beta-Lactamase Inhibitors pharmacology, beta-Lactamase Inhibitors chemistry, Boronic Acids pharmacology, Boronic Acids chemistry, beta-Lactamases metabolism, Microbial Sensitivity Tests, Acinetobacter baumannii drug effects, Acinetobacter baumannii enzymology, Anti-Bacterial Agents pharmacology, Anti-Bacterial Agents chemistry, Bacterial Proteins antagonists & inhibitors, Bacterial Proteins metabolism
- Abstract
The relative inhibitory activities of diazabicyclooctanes (avibactam, relebactam, zidebactam, nacubactam, durlobactam), boronic acid derivatives (vaborbactam, taniborbactam, xeruborbactam), and penicillin-based sulfone derivative enmetazobactam were evaluated against several intrinsic and acquired class C β-lactamases. By contrast to vaborbactam and enmetazobactam, taniborbactam, xeruborbactam, and all diazabicyclooctanes demonstrated effective activities against most AmpC enzymes. Notably, durlobactam exhibited the most pronounced inhibitory effect. Interstingly, the chromosomal AmpC of Acinetobacter baumannii was the least sensitive enzyme to the newly developed β-lactamase inhibitors., Competing Interests: The authors declare no conflict of interest.
- Published
- 2024
- Full Text
- View/download PDF